MGX
Metagenomi, Inc. Common StockNASDAQHealthcare$1.35+0.75%ClosedMarket Cap: $50.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.32
P/S
2.01
EV/EBITDA
-0.56
DCF Value
$-104.95
FCF Yield
-176.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.3%
Operating Margin
-380.9%
Net Margin
-348.5%
ROE
-47.1%
ROA
-39.7%
ROIC
-47.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.9M | 66.8% | $-24.4M | $-22.5M | $-0.60 | — |
| FY 2025 | $25.2M | 78.9% | $-96.0M | $-87.9M | $-2.36 | — |
| Q3 2025 | $8.7M | 84.7% | $-22.8M | $-20.4M | $-0.55 | — |
| Q2 2025 | $8.5M | -164.4% | $-21.0M | $-19.9M | $-0.54 | — |
| Q1 2025 | $4.1M | 100.0% | $-27.8M | $-25.0M | $-0.68 | — |
| Q4 2024 | $9.6M | 100.0% | $-20.6M | $-23.4M | $-0.63 | — |
| FY 2024 | $52.3M | 100.0% | $-88.9M | $-78.1M | $-2.09 | — |
| Q3 2024 | $11.5M | 100.0% | $-22.4M | $-18.8M | $-0.51 | — |
| Q2 2024 | $20.0M | 100.0% | $-16.9M | $-10.7M | $-0.29 | — |
| Q1 2024 | $11.2M | -181.7% | $-29.0M | $-25.1M | $-0.67 | — |
| Q4 2023 | $12.4M | -99.7% | $-20.2M | $-19.3M | $-0.51 | — |
| FY 2023 | $44.8M | -110.9% | $-78.5M | $-68.3M | $-1.82 | — |